Shift Bioscience

About:

Simulation guided target discovery for age-linked diseases

Website: https://www.shiftbioscience.com

Twitter/X: ShiftBioscience

Top Investors: Business Growth Fund, F-Prime Capital, Jonathan Milner, Kindred Capital, Meltwind Advisory

Description:

Shift Bioscience is using simulation guided cell rejuvenation to defeat the diseases of aging. Cellular reprogramming with Yamanaka factors can reverse aging in the dish but is not yet safe for clinical use. Shift has pioneered the first high-throughput, high-accuracy aging biomarker, which has been leveraged inside AI-based cell simulations to identify safer rejuvenation gene-factors. Shift envisions the development of a single drug-family that can treat multiple diseases of aging, after which full and continued health into old age becomes accessible by simple prescription.

Total Funding Amount:

12.5M GBP

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Cambridge, Cambridgeshire, United Kingdom

Founded Date:

2017-07-01

Contact Email:

hello(AT)shiftbioscience.com

Founders:

Brendan Swain, Daniel Ives

Number of Employees:

11-50

Last Funding Date:

2024-10-15

IPO Status:

Private

© 2024 MyAiNote.com